DOCSLIB.ORG

Product List Subcatalog Biochemica

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Product Article Name Package Product Article Name Package number Productsize Listnumber size Subcatalog Biochemica Take the pink Link! www. .com AppliChem gmbH AppliChem Scandinavia AppliChem Inc. Ottoweg 4 Lyngby Storcenter 66, Lejl. 1203 2814 Mary Avenue D-64291 Darmstadt DK-2800 Kongens Lyngby 63144 St. Louis Germany Denmark Missouri, USA Phone +49 6151 9357-0 Phone +45 39 64 46 66 Phone +1 314 968-3331 Fax +49 6151 9357-11 Fax +45 39 64 34 81 Fax +1 314 968-5006 eMail [email protected] eMail [email protected] eMail [email protected] www.applichem.com Article number Name Package Article number Name Package size size A2110,0005 A23187 5 mg A9541,0010 3-Acetyl-9-11-dehydro-beta-boswel- 10 mg lic acid HPLC grade A2110,0010 A23187 10 mg A5269,0020 6-O-Acetylacteoside HPLC grade 20 mg A7847,0005 A23187 calcium magnesium salt 5 mg BioChemica A5269,0050 6-O-Acetylacteoside HPLC grade 50 mg A1088,0001 ABTS® BioChemica 1 g A3753,0010 Acetyl-Coenzym A trilithium salt 10 mg BioChemica A1088,0005 ABTS® BioChemica 5 g ® A3753,0050 Acetyl-Coenzym A trilithium salt 50 mg A1088,0010 ABTS BioChemica 10 g BioChemica A7817,0020 Acacetin HPLC grade 20 mg A3753,0100 Acetyl-Coenzym A trilithium salt 100 mg A7817,0050 Acacetin HPLC grade 50 mg BioChemica A1060,0100 ACES Buffer grade 100 g A8502,0005 3-Acetyldeoxynivalenol 5 mg A1060,0250 ACES Buffer grade 250 g A7451,0001 N-Acetyl-D-galactosamine 1 g A1060,1000 ACES Buffer grade 1 kg A7451,0005 N-Acetyl-D-galactosamine 5 g A3986,0025 ACES Molecular biology grade 25 g A2554,0025 N-Acetyl-D-glucosamine 25 g BioChemica A1464,0050 Acetamide Molecular biology grade 50 g A2554,0100 N-Acetyl-D-glucosamine 100 g A1464,0100 Acetamide Molecular biology grade 100 g BioChemica A3701,1000GL Acetic acid 100 % BioChemica 1 L A2554,0250 N-Acetyl-D-glucosamine 250 g A3701,1000PE Acetic acid 100 % BioChemica 1 L BioChemica A3701,2500GL Acetic acid 100 % BioChemica 2,5 L A8174,0025 N-Acetyl-L-cysteine BioChemica 25 g (non animal origin) A3701,2500PE Acetic acid 100 % BioChemica 2,5 L A8174,0100 N-Acetyl-L-cysteine BioChemica 100 g A3686,0500 Acetic acid 500 ml (non animal origin) 100 % Molecular biology grade A8174,0500 N-Acetyl-L-cysteine BioChemica 500 g A3686,1000 Acetic acid 1 L (non animal origin) 100 % Molecular biology grade A3755,0005 N-Acetyl-L-tyrosine ethyl ester 5 g A3686,2500 Acetic acid 2,5 L monohydrate (ATEE) BioChemica 100 % Molecular biology grade A3754,0005 Acetylthiocholine iodide BioChemica 5 g A1941,0005 Acetoacetic acid lithium salt 5 g BioChemica A3754,0025 Acetylthiocholine iodide BioChemica 25 g A1941,0250 Acetoacetic acid lithium salt 250 mg A5321,0010 3-Acetyl-α-boswellic acid 10 mg BioChemica HPLC grade A3855,1000 Acetone BioChemica 1 L A5321,0020 3-Acetyl-α-boswellic acid 20 mg HPLC grade A3855,2500 Acetone BioChemica 2,5 L A5280,0010 3-Acetyl-β-boswellic acid 10 mg A0934,1000 Acetonitrile DNA synthesis and 1 L HPLC grade peptide sequencing grade A5280,0020 3-Acetyl-β-boswellic acid 20 mg A2051,0025 Acetoxy valerenic acid HPLC grade 25 mg HPLC grade A2051,0025DOC Acetoxy valerenic acid HPLC grade 25 mg A6934,0100 α1-Acid Glycoprotein, human 100 µg A3752,0100 Acetyl chloride BioChemica 100 ml A1398,0010 Acridine orange (C.I. 46005) 10 g A5262,0010 3-Acetyl-11-keto-β-boswellic acid 10 mg A1398,0025 Acridine orange (C.I. 46005) 25 g HPLC grade A1398,0100 Acridine orange (C.I. 46005) 100 g A5262,0020 3-Acetyl-11-keto-β-boswellic acid 20 mg HPLC grade A2952,0010 Acriflavine hydrochloride 10 g BioChemica A9541,0005 3-Acetyl-9-11-dehydro-beta- 5 mg boswellic acid HPLC grade alphabetic List BioChemicals 2013 • AppliChem 1 Article number Name Package Article number Name Package size size A2952,0050 Acriflavine hydrochloride 50 g A4989,1000 Acrylamide - Solution (40 %) - 1 L BioChemica Mix 37.5 : 1 Molecular biology grade A2952,0250 Acriflavine hydrochloride 250 g A3632,0500 Acrylamide - Solution (40 %) 500 ml BioChemica Molecular biology grade A0941,1000 Acrylamide - Diluent 1 L A3632,1000 Acrylamide - Solution (40 %) 1 L for sequencing gels Molecular biology grade A0933,0500 Acrylamide - Sequencing buffer 500 ml A1089,0500 Acrylamide 2K Standard grade, 500 g extrapure A3857,0250 Acrylamide - Solution (30 %) - 250 ml Mix 19 : 1 Molecular biology grade A1089,1000 Acrylamide 2K Standard grade, 1 kg extrapure A3857,0500 Acrylamide - Solution (30 %) - 500 ml Mix 19 : 1 Molecular biology grade A1089,5000 Acrylamide 2K Standard grade, 5 kg extrapure A3857,1000 Acrylamide - Solution (30 %) - 1 L Mix 19 : 1 Molecular biology grade A1155,0100 Acrylamide 4K - Mix 19 : 1 (Powder) 100 g A4983,0250 Acrylamide - Solution (30 %) - 250 ml A1155,0500 Acrylamide 4K - Mix 19 : 1 (Powder) 500 g Mix 29 : 1 Molecular biology grade A0956,0100 Acrylamide 4K - Mix 29 : 1 (Powder) 100 g A4983,0500 Acrylamide - Solution (30 %) - 500 ml Mix 29 : 1 Molecular biology grade A0956,0500 Acrylamide 4K - Mix 29 : 1 (Powder) 500 g A4983,1000 Acrylamide - Solution (30 %) - 1 L A1156,0100 Acrylamide 4K - Mix 32 : 1 (Powder) 100 g Mix 29 : 1 Molecular biology grade A1156,0500 Acrylamide 4K - Mix 32 : 1 (Powder) 500 g A3626,0250 Acrylamide - Solution (30 %) - 250 ml A1157,0100 Acrylamide 4K - Mix 37.5 : 1 100 g Mix 37.5 : 1 Molecular biology grade (Powder) A3626,0500 Acrylamide - Solution (30 %) - 500 ml A1157,0500 Acrylamide 4K - Mix 37.5 : 1 500 g Mix 37.5 : 1 Molecular biology grade (Powder) A3626,1000 Acrylamide - Solution (30 %) - 1 L A0738,0500 Acrylamide 4K - Ready-to-use 500 ml Mix 37.5 : 1 Molecular biology grade solution for denaturing DNA-PAGE A3651,0250 Acrylamide - Solution (30 %) 250 ml (10 %) Molecular biology grade A0733,0500 Acrylamide 4K - Ready-to-use soluti- 500 ml A3651,1000 Acrylamide - Solution (30 %) 1 L on for denaturing DNA-PAGE (4 %) Molecular biology grade A0734,0500 Acrylamide 4K - Ready-to-use soluti- 500 ml A3658,0250 Acrylamide - Solution (40 %) - 250 ml on for denaturing DNA-PAGE (5 %) Mix 19 : 1 Molecular biology grade A0735,0500 Acrylamide 4K - Ready-to-use soluti- 500 ml A3658,0500 Acrylamide - Solution (40 %) - 500 ml on for denaturing DNA-PAGE (6 %) Mix 19 : 1 Molecular biology grade A0736,0500 Acrylamide 4K - Ready-to-use soluti- 500 ml A3658,1000 Acrylamide - Solution (40 %) - 1 L on for denaturing DNA-PAGE (8 %) Mix 19 : 1 Molecular biology grade A0725,0500 Acrylamide 4K - Ready-to-use 500 ml A0385,0250 Acrylamide - Solution (40 %) - 250 ml solution for non-denaturing Mix 29 : 1 Molecular biology grade DNA-PAGE (12 %) A0385,0500 Acrylamide - Solution (40 %) - 500 ml A0726,0500 Acrylamide 4K - Ready-to-use 500 ml Mix 29 : 1 Molecular biology grade solution for non-denaturing DNA-PAGE (15 %) A0385,1000 Acrylamide - Solution (40 %) - 1 L Mix 29 : 1 Molecular biology grade A0727,0500 Acrylamide 4K - Ready-to-use 500 ml solution for non-denaturing A4989,0250 Acrylamide - Solution (40 %) - 250 ml DNA-PAGE (20 %) Mix 37.5 : 1 Molecular biology grade A0721,0500 Acrylamide 4K - Ready-to-use 500 ml A4989,0500 Acrylamide - Solution (40 %) - 500 ml solution for non-denaturing Mix 37.5 : 1 Molecular biology grade DNA-PAGE (3.5 %) 2 alphabetic List BioChemicals 2013 • AppliChem Article number Name Package Article number Name Package size size A0722,0500 Acrylamide 4K - Ready-to-use 500 ml A1672,0500 Acrylamide 4K - Solution (30 %) - 500 ml solution for non-denaturing Mix 37.5 : 1 DNA-PAGE (5 %) A1672,1000 Acrylamide 4K - Solution (30 %) - 1 L A0723,0500 Acrylamide 4K - Ready-to-use 500 ml Mix 37.5 : 1 solution for non-denaturing DNA-PAGE (6 %) A3381,0500 Acrylamide 4K - Solution (30 %) - 500 ml Mix 49 : 1 A0724,0500 Acrylamide 4K - Ready-to-use 500 ml solution for non-denaturing A3381,1000 Acrylamide 4K - Solution (30 %) - 1 L DNA-PAGE (8 %) Mix 49 : 1 A0711,0500 Acrylamide 4K - Ready-to-use 500 ml A0962,0500 Acrylamide 4K - Solution (40 %) 500 ml solution for SDS-PAGE (10 %) A0962,1000 Acrylamide 4K - Solution (40 %) 1 L A0712,0500 Acrylamide 4K - Ready-to-use 500 ml A1640,0500 Acrylamide 4K - Solution (40 %) - 500 ml solution for SDS-PAGE (12.5 %) Mix 19 : 1 A0713,0500 Acrylamide 4K - Ready-to-use 500 ml A1640,1000 Acrylamide 4K - Solution (40 %) - 1 L solution for SDS-PAGE (15 %) Mix 19 : 1 A0709,0500 Acrylamide 4K - Ready-to-use 500 ml A0950,0500 Acrylamide 4K - Solution (40 %) - 500 ml solution for SDS-PAGE (5 %) Mix 29 : 1 A0710,0500 Acrylamide 4K - Ready-to-use 500 ml A0950,1000 Acrylamide 4K - Solution (40 %) - 1 L solution for SDS-PAGE (7.5 %) Mix 29 : 1 A4850,0500 Acrylamide 4K - Sequamix 4 500 ml A0946,0500 Acrylamide 4K - Solution (40 %) - 500 ml A2108,0500 Acrylamide 4K - Sequamix 6 500 ml Mix 32 : 1 A2109,0500 Acrylamide 4K - Sequamix 8 500 ml A0946,1000 Acrylamide 4K - Solution (40 %) - 1 L Mix 32 : 1 A1891,0500 Acrylamide 4K - 500 ml Sequencing solution (25 %) 19 : 1 A1577,0500 Acrylamide 4K - Solution (40 %) - 500 ml Mix 37.5 : 1 A1891,1000 Acrylamide 4K - 1 L Sequencing solution (25 %) 19 : 1 A1577,1000 Acrylamide 4K - Solution (40 %) - 1 L Mix 37.5 : 1 A1673,0500 Acrylamide 4K - 500 ml Sequencing solution (40 %) 19 : 1 A9546,0500 Acrylamide 4K - Solution (40 %) - 500 ml Mix 49 : 1 for SSCP A1673,1000 Acrylamide 4K - 1 L Sequencing solution (40 %) 19 : 1 A2556,0500 Acrylamide 4K - Solution (50 %) - 500 ml Mix 16.6 : 1 A1154,0500 Acrylamide 4K - Solution (30 %) 500 ml A3756,0500 Acrylamide 4K - Solution (63.9 %) - 500 ml A1154,1000 Acrylamide 4K - Solution (30 %) 1 L Mix 158.75 : 1 for TAU gels A0967,0500 Acrylamide 4K - Solution (30 %) - 500 ml A2529,0250 Acrylamide 4K - Stacking gel soluti- 250 ml Mix 19 : 1 on (4 %) for SDS-PAGE A0967,1000 Acrylamide 4K - Solution
Recommended publications
  • Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug

    Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug

    Downloaded from molpharm.aspetjournals.org at ASPET Journals on September 23, 2021 page 1 nd Interaction with the Human Multidrug Multidrug Human the with nd Interaction This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version.
  • Analytical Performance of an Immunoassay to Measure Proenkephalin ⁎ Leslie J

    Analytical Performance of an Immunoassay to Measure Proenkephalin ⁎ Leslie J

    Clinical Biochemistry xxx (xxxx) xxx–xxx Contents lists available at ScienceDirect Clinical Biochemistry journal homepage: www.elsevier.com/locate/clinbiochem Analytical performance of an immunoassay to measure proenkephalin ⁎ Leslie J. Donatoa, ,Jeffrey W. Meeusena, John C. Lieskea, Deborah Bergmannc, Andrea Sparwaßerc, Allan S. Jaffea,b a Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States b Division of Cardiology, Mayo Clinic, Rochester, MN 55905, United States c Sphingotec GmbH, Hennigsdorf, Germany ARTICLE INFO ABSTRACT Keywords: Background: Endogenous opioids, enkephalins, are known to increase with acute kidney injury. Since the mature Biomarkers pentapeptides are unstable, we evaluated the performance of an assay that measures proenkephalin 119–159 Proenkephalin (PENK), a stable peptide formed concomitantly with mature enkephalins. Enkephalin Methods: PENK assay performance was evaluated on two microtiterplate/chemiluminescence sandwich im- Pro-enkephalin munoassay formats that required 18 or 1 h incubation times. PENK concentration was measured in plasma from penKid healthy individuals to establish a reference interval and in patients with varied levels of kidney function and Assay validation comorbidities to assess the association with measured glomerular filtration rate (mGFR) using iothalamate clearance. Results: Assay performance characteristics in plasma were similar between the assay formats. Limit of quanti- tation was 26.0 pmol/L (CV = 20%) for the 1 h assay and 17.3 pmol/L (CV = 3%) for the 18 h assay. Measurable ranges were 26–1540 pmol/L (1 h assay) and 18–2300 pmol/L (18 h assay). PENK concentrations are stable in plasma stored ambient to 10 days, refrigerated to at least 15 days, and frozen to at least 90 days.
  • TECHNISCHE UNIVERSITÄT MÜNCHEN Large Scale

    TECHNISCHE UNIVERSITÄT MÜNCHEN Large Scale

    TECHNISCHE UNIVERSITÄT MÜNCHEN Lehrstuhl für Genomorientierte Bioinformatik Large Scale Knowledge Extraction from Biomedical Literature Based on Semantic Role Labeling Thorsten Barnickel Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzende: Univ.‐Prof. Dr. I. Antes Prüfer der Dissertation: 1. Univ.‐Prof. Dr. H.‐W. Mewes 2. Univ.‐Prof. Dr. R. Zimmer (Ludwig‐Maximilians‐Universität München) Die Dissertation wurde am 30. Juli bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 25. November 2009 angenommen. ACKNOWLEDGEMENTS First and foremost, I would like to express my deep gratitude to my promoter Dr. Volker Stümpflen. Without his continuing, stimulating encouragement and his excellent background in Enterprise technologies still being predominantly used in the IT-industry rather than in academic research, I would not have been able to finish my doctorate in the presented form. Facing the tremendous amount of data that was generated by gathering the positional information of millions of biomedical terms, I was close to cutting the project down to a notably smaller version compared to the text mining system presented in this thesis. Volkers knowledge on database servers and performance tuning significantly contributed to the development of a database schema finally being able to cope with the immense amount of data. I would also like to cordially thank Prof. Dr. Hans-Werner Mewes, head of the Institute for Bioinformatics and Systems Biology (IBIS), for giving me the opportunity to do my doctorate at his institute and for his friendly support and encouragement all along my time at IBIS.
  • St. John's Wort 2018

    St. John's Wort 2018

    ONLINE SERIES MONOGRAPHS The Scientific Foundation for Herbal Medicinal Products Hyperici herba St. John's Wort 2018 www.escop.com The Scientific Foundation for Herbal Medicinal Products HYPERICI HERBA St. John's Wort 2018 ESCOP Monographs were first published in loose-leaf form progressively from 1996 to 1999 as Fascicules 1-6, each of 10 monographs © ESCOP 1996, 1997, 1999 Second Edition, completely revised and expanded © ESCOP 2003 Second Edition, Supplement 2009 © ESCOP 2009 ONLINE SERIES ISBN 978-1-901964-61-5 Hyperici herba - St. John's Wort © ESCOP 2018 Published by the European Scientific Cooperative on Phytotherapy (ESCOP) Notaries House, Chapel Street, Exeter EX1 1EZ, United Kingdom www.escop.com All rights reserved Except for the purposes of private study, research, criticism or review no part of this text may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, without the written permission of the publisher. Important Note: Medical knowledge is ever-changing. As new research and clinical experience broaden our knowledge, changes in treatment may be required. In their efforts to provide information on the efficacy and safety of herbal drugs and herbal preparations, presented as a substantial overview together with summaries of relevant data, the authors of the material herein have consulted comprehensive sources believed to be reliable. However, in view of the possibility of human error by the authors or publisher of the work herein, or changes in medical knowledge, neither the authors nor the publisher, nor any other party involved in the preparation of this work, warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for results obtained by the use of such information.
  • Taxifolin: a Wonder Molecule in Making Multiple Drug Targets

    Taxifolin: a Wonder Molecule in Making Multiple Drug Targets

    Short Communication Annals of Pharmacology and Pharmaceutics Published: 22 Aug, 2017 Taxifolin: A Wonder Molecule in Making Multiple Drug Targets Utkarsh Raj, Imlimaong Aier and Pritish Kumar Varadwaj* Department of Bioinformatics and Applied Sciences, Indian Institute of Information Technology, Allahabad, India Keywords Taxifolin; Anti-cancerous; Anti-ebola; Anti-oxidant; Anti-inflammatory Short Communication Taxifolin (often referred to as dihydroquercetin) is a flavanonol which is a part of the phytonutrient family (a set of chemical materials that occur evidently in flora and have more than one fitness benefits however aren't taken into consideration vital to human fitness). Taxifolin has been observed in a variety of cone bearing gymnosperms, like, Pinus roxburghii [1], Cedrus deodara [1], Larix sibirica (the Russian or Siberian larch) and inside the Chinese yew, Taxus chinensis var. mairei [2]. Its presence has also been reported in silymarin extract from the milk thistle seeds and cherry wood aged vinegar [3]. The 2D structure of Taxifolin has been depicted in Figure1. Over the past 50 years, almost six hundred studies (mostly conducted in Russia) have investigated the efficacy and protection of taxifolin. The important roles of the compound Taxifolin has been elucidated in Figure 2. The main highlights of this compound are its antioxidant efficiency and vascular-defensive movement. Taxifolin has also been shown to provide benefits to cardiovascular health, the pores and skin, cognitive feature, contamination, allergic reactions and immunodeficiency, in addition to the fitness of diabetics. Amongst others, research has examined that taxifolin is a brilliant antioxidant, far more effective than dietary carotenoids and it lowers blood viscosity and improves capillary microcirculation.
  • Journal of the Hellenic Veterinary Medical Society

    Journal of the Hellenic Veterinary Medical Society

    Journal of the Hellenic Veterinary Medical Society Vol. 71, 2020 Isobolographic analysis of analgesic interactions of silymarin with ketamine in mice NASER A.S. Department of physiology, biochemistry and pharmacology, Faculty of Veterinary Medicine, University of Mosul, Mosul, Iraq ALBADRANY Y. Department of physiology, biochemistry and pharmacology, Faculty of Veterinary Medicine, University of Mosul, Mosul, Iraq SHAABAN K.A. [email protected] https://doi.org/10.12681/jhvms.23653 Copyright © 2020 A.S. NASER, Y. ALBADRANY, K.A. SHAABAN To cite this article: NASER, A.S., ALBADRANY, Y., & SHAABAN, K.A. (2020). Isobolographic analysis of analgesic interactions of silymarin with ketamine in mice. Journal of the Hellenic Veterinary Medical Society, 71(2), 2171-2178. doi:https://doi.org/10.12681/jhvms.23653 http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 23/09/2021 18:43:31 | J HELLENIC VET MED SOC 2020, 71(2): 2171-2178 Research article ΠΕΚΕ 2020, 71(2): 2171-2178 Ερευνητικό άρθρο Isobolographic analysis of analgesic interactions of silymarin with ketamine in mice A.S. Naser1*, Y. Albadrany2, K.A. Shaaban2 1Department of physiology, biochemistry and pharmacology, Faculty of Veterinary Medicine, University of Mosul, Mosul, Iraq 2Department of physiology, biochemistry and pharmacology, Faculty of Veterinary Medicine, University of Mosul, Mosul, Iraq ABSTRACT: The present study was undertaken to explore the analgesic effect of silymarin and ketamine alone or in combination in mice. Analgesia was measured by using a hot plate and the writhing test. The up-and-down method was used to determine the median effective analgesic dosages (ED50s) of silymarin and ketamine administered intraper- itoneally (ip) either alone or together.
  • Antitumor Activity of Actinonin in Vitro and in Vivo

    Antitumor Activity of Actinonin in Vitro and in Vivo

    Vol. 4, 171-176, January 1998 Clinical Cancer Research 171 Antitumor Activity of Actinonin in Vitro and in Vivo Yang Xu, Lawrence T. Lai, Janice L. Gabrilove, 8), mye!oid and monocytic cells, and most myeloblastic leuke- and David A. Scheinberg’ mias as well as on cells and tissues outside the hematopoietic system including fibroblasts, intestinal epithelium, renal tubular Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 epithelium, and synaptic membranes of the central nervous system (I ). APN occurs as a homodimer, and the molecule is a 150-kDa, transmembrane glycoprotein with an intracellular ABSTRACT amino terminus (1). F23, an antihuman CD13/APN mAb, is able Actinonin, an antibiotic and CD13/aminopeptidase N to completely block the active site of the enzyme (9). (APN) inhibitor, has been shown to be cytotoxic to tumor Bestatin, a CD 1 3/APN inhibitor, was examined in preclin- cell lines in vitro. We investigated the antiproliferative ef- ical and clinical studies; bestatin could inhibit lymph node fects of actinonin on human and murine leukemia and lym- metastasis of P388 leukemia in mice (10) and was used in phoma cells. Actinonin inhibited growth of NB4 and HL6O clinical trials in malignant skin tumors (1 1), in head and neck human cell lines and AKR mouse leukemia cells in vitro with cancer (12), in esophageal cancer (13), and in gynecologic an IC50 of about 2-S g/ml. The inhibitory effect on CD13- tumors (14). High doses of bestatin resulted in the significant positive cells was not blocked by pretreatment with the inhibition of preexisting experimental and spontaneous metas- anti-CD13/APN monoclonal antibody F23, which binds with tasis in mice (15).
  • Epicatechin and Taxifolin Relevant for the Treatment of Hypertension and Viral Infection: Knowledge from Preclinical Studies

    Epicatechin and Taxifolin Relevant for the Treatment of Hypertension and Viral Infection: Knowledge from Preclinical Studies

    antioxidants Review Mechanisms Modified by (−)-Epicatechin and Taxifolin Relevant for the Treatment of Hypertension and Viral Infection: Knowledge from Preclinical Studies Iveta Bernatova 1,* and Silvia Liskova 1,2 1 Centre of Experimental Medicine, Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Sienkiewiczova 1, 813 71 Bratislava, Slovakia; [email protected] 2 Faculty of Medicine, Institute of Pharmacology and Clinical Pharmacology, Comenius University, Sasinkova 4, 811 08 Bratislava, Slovakia * Correspondence: [email protected]; Tel.: +421-2-32296013 Abstract: Various studies have shown that certain flavonoids, flavonoid-containing plant extracts, and foods can improve human health. Experimental studies showed that flavonoids have the capacity to alter physiological processes as well as cellular and molecular mechanisms associated with their antioxidant properties. An important function of flavonoids was determined in the cardiovascular system, namely their capacity to lower blood pressure and to improve endothelial function. (−)- Epicatechin and taxifolin are two flavonoids with notable antihypertensive effects and multiple beneficial actions in the cardiovascular system, but they also possess antiviral effects, which may be of particular importance in the ongoing pandemic situation. Thus, this review is focused on the Citation: Bernatova, I.; Liskova, S. current knowledge of (−)-epicatechin as well as (+)-taxifolin and/or (−)-taxifolin-modified biological Mechanisms Modified by action and underlining molecular mechanisms determined in preclinical studies, which are relevant − ( )-Epicatechin and Taxifolin not only to the treatment of hypertension per se but may provide additional antiviral benefits that Relevant for the Treatment of could be relevant to the treatment of hypertensive subjects with SARS-CoV-2 infection. Hypertension and Viral Infection: Knowledge from Preclinical Studies.
  • Assembling the Puzzle of Taxifolin Polymorphism

    Assembling the Puzzle of Taxifolin Polymorphism

    molecules Article Assembling the Puzzle of Taxifolin Polymorphism Roman P. Terekhov 1,* , Irina A. Selivanova 1, Nonna A. Tyukavkina 1, Igor R. Ilyasov 1, Anastasiya K. Zhevlakova 1, Alexander V. Dzuban 2, Anatoliy G. Bogdanov 3, Georgiy N. Davidovich 3, Gennadii V. Shylov 4, Andrey N. Utenishev 1,4, Dmitriy Yu. Kovalev 5 , Anatoliy A. Fenin 6 and Tatyana G. Kabluchko 7 1 Department of Chemistry, Sechenov First Moscow State Medical University, Trubetskaya st. 8-2, 119991 Moscow, Russia; [email protected] (I.A.S.); [email protected] (N.A.T.); [email protected] (I.R.I.); [email protected] (A.K.Z.); [email protected] (A.N.U.) 2 Department of Chemistry, Lomonosov Moscow State University, Leninskiye Gory 1-3, 119991 Moscow, Russia; [email protected] 3 Faculty of Biology, Lomonosov Moscow State University, Leninskiye Gory 1-32, 119991 Moscow, Russia; [email protected] (A.G.B.); [email protected] (G.N.D.) 4 Laboratory of Structural Chemistry, Institute of Problems of Chemical Physics, Russian Academy of Sciences, Acad. Semenov av. 1, 143432 Chernogolovka, Russia; [email protected] 5 Laboratory of X-ray Investigation, Merzhanov Institute of Structural Macrokinetics and Materials Science, Russian Academy of Sciences, Acad. Osipyan str. 8, 142432 Chernogolovka, Russia; [email protected] 6 Institute of Materials for Modern Power Engineering and Nanotechnology, Mendeleev University of Chemical Technology of Russia, Miusskaya sq. 9, 125947 Moscow, Russia; [email protected] 7 Department of Technology, Ametis JSC, Naberezhnaya st. 68, 675000 Blagoveshchensk, Russia; [email protected] * Correspondence: terekhov_r_p@staff.sechenov.ru; Tel.: +7-965-232-5122 Academic Editor: Carlos Eduardo Sabino Bernardes Received: 15 October 2020; Accepted: 16 November 2020; Published: 20 November 2020 Abstract: A large amount of the current literature dedicated to solid states of active pharmaceutical ingredients (APIs) pays special attention to polymorphism of flavonoids.
  • Assessment Report on Hypericum Perforatum L., Herba

    Assessment Report on Hypericum Perforatum L., Herba

    European Medicines Agency Evaluation of Medicines for Human Use London, 12 November 2009 Doc. Ref.: EMA/HMPC/101303/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) ASSESSMENT REPORT ON HYPERICUM PERFORATUM L., HERBA 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: [email protected] http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged TABLE OF CONTENTS I. REGULATORY STATUS OVERVIEW...................................................................................4 II. ASSESSMENT REPORT............................................................................................................5 II.1 INTRODUCTION..........................................................................................................................6 II.1.1 Description of the herbal substance(s), herbal preparation(s) or combinations thereof 6 II.1.1.1 Herbal substance:........................................................................................................ 6 II.1.1.2 Herbal preparation(s): ................................................................................................ 7 II.1.1.3 Combinations of herbal substance(s) and/or herbal preparation(s)........................... 9 Not applicable. ................................................................................................................................9 II.1.1.4 Vitamin(s) ...................................................................................................................
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Kidney Stones

    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Kidney Stones

    Dr.
  • Identification and Functional Characterization of the First Two

    Identification and Functional Characterization of the First Two

    Identification and functional characterization of the first two aromatic prenyltransferases implicated in the biosynthesis of furanocoumarins and prenylated coumarins in two plant families: Rutaceae and Apiaceae Fazeelat Karamat To cite this version: Fazeelat Karamat. Identification and functional characterization of the first two aromatic prenyl- transferases implicated in the biosynthesis of furanocoumarins and prenylated coumarins in two plant families: Rutaceae and Apiaceae. Agronomy. Université de Lorraine, 2013. English. NNT : 2013LORR0029. tel-01749560 HAL Id: tel-01749560 https://hal.univ-lorraine.fr/tel-01749560 Submitted on 29 Mar 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. AVERTISSEMENT Ce document est le fruit d'un long travail approuvé par le jury de soutenance et mis à disposition de l'ensemble de la communauté universitaire élargie. Il est soumis à la propriété intellectuelle de l'auteur. Ceci implique une obligation de citation et de référencement lors de l’utilisation de ce document. D'autre part, toute contrefaçon, plagiat,